Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zolmitriptan - AstraZeneca/Burroughs Wellcome

Drug Profile

Zolmitriptan - AstraZeneca/Burroughs Wellcome

Alternative Names: 311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomig-ZMT; Zomigon

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Burroughs Wellcome
  • Developer Amneal Pharmaceuticals; AstraZeneca
  • Class Analgesics; Antimigraines; Indoles; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cluster headache; Menstrual migraine; Migraine

Most Recent Events

  • 01 Oct 2022 IMPAX Laboratories in collaboration with AstraZeneca terminates phase III trial in Migraine due to slow enrollment (In Children) in USA (Intranasal) (NCT03275922)
  • 06 Jan 2020 Zolmitriptan is still in phase III for Migraine (In children) in USA (Intranasal) (NCT03275922)
  • 05 Dec 2018 Zolmitriptan licensed to Grunenthal for worldwide commercialisation excluding Japan for the treatment of acute migraines and cluster headaches before December 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top